A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment.

ABSTRACT:

Abstract

T-cell bispecific antibodies (T-BsAbs) such as blinatumomab hold great promise for cancer immunotherapy. A better understanding of the in vivo immune response induced by T-BsAbs is crucial to improving their efficacy and safety profile. However, such efforts are hindered by the limitations of current preclinical models. To address this, we developed a syngeneic murine model with humanized CD3 and target antigen (CD20). This model enables the development of disseminated leukemia with a high tumor burden, which mirrors clinical findings in human patients with relapsed/refractory acute lymphoblastic leukemia. Treatment of this model with T-BsAbs results in cytokine release syndrome, with cytokine profiles and levels reflecting observations made in human patients. This model a

SUBMITTER: Wang L 

PROVIDER: S-EPMC10837186 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature